ScripsAmerica, a leading supplier of prescription, OTC, and nutraceutical drugs for retail pharmacies, hospitals, long-term care facilities, and government and home care agencies, has signed an agreement with Capricorn Pharma, Inc. (CPI) for the development, manufacturing, and supply of ScripsAmerica’s RapiMed® children’s pain reliever and fever reducer.
CPI will manufacture and distribute RapiMed® within the U.S. and North America under an initial two-year contract with two five-year extension options. Terms of the agreement call for CPI to manufacture and distribute a minimum of 20 million tablets; both parties expect annual production growth with a projected volume of approximately 97 million RapiMed® tablets being distributed in the agreement’s seventh year.
ScripsAmerica anticipates launching its RapiMed® product in September of this year, and company CEO Bob Schneiderman emphasized the value he expects CPI to generate for the product roll-out.
“This is an exciting and important development for the company as we prepare for our anticipated RapiMed® product launch later this year. CPI is a very reputable manufacturer in the generic drug market and we are confident that our relationship will be very productive and beneficial for ScripsAmerica and its shareholders,” he stated in the press release.
For more information visit www.ScripsAmerica.com or www.capricornpharma.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment